Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

ABSTRACTThis phase-3, double-blind, placebo-controlled study (NCT04228783) evaluated lot-to-lot consistency of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. Participants were randomized (6:6:6:1) to receive the two-dose regimen from three consecutively manufactured lots of Ad26.ZEBOV on Day 1 p...

Full description

Bibliographic Details
Main Authors: Neil Goldstein, Chelsea McLean, Auguste Gaddah, Joachim Doua, Babajide Keshinro, Linda Bus-Jacobs, Jenny Hendriks, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Ebola
Ad26.ZEBOV
MVA-BN-Filo
vaccine
immunogenicity
clinical trial
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2327747

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2327747

Similar Items